CONNECT WITH US:
Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
Dec 06, 2018 09:24 JST
Eisai Co., Ltd. and University College London (UCL) announced today that they have commenced preparations for Phase I clinical studies on E2814, the first clinical candidate from their drug discovery collaboration, in Alzheimer's disease patients within fiscal 2018.
Eisai: MOVICOL Launched in Japan
Nov 29, 2018 13:48 JST
MOVICOL is the first polyethylene glycol preparation indicated for treatment of chronic constipation in Japan, available for adults and children 2 years of age and older.
Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa
Nov 28, 2018 10:55 JST
Eisai Co., Ltd. announced today that based on topline results, the primary efficacy endpoint was met in a Phase III clinical study (Study 342) conducted for submission in Japan, which evaluated its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) as monotherapy for partial-onset seizures.
Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium
Nov 27, 2018 17:02 JST
Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS).
Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting
Nov 23, 2018 07:14 JST
Eisai Co., Ltd. announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 72nd American Epilepsy Society Annual Meeting (AES 2018) to be held from November 30 to December 4, 2018 in New Orleans in the United States.
Eisai Receives "IR Grand Prix Award"
Nov 14, 2018 12:30 JST
Eisai Co., Ltd. has announced that it received the "IR Grand Prix Award" at the IR Award 2018 held by the Japan Investor Relations Association (JIRA).
Eisai Launches Lenvima (Lenvatinib) in China
Nov 12, 2018 11:51 JST
Eisai Co., Ltd. announced that its Chinese subsidiary Eisai China Inc. (ECI) has launched the kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in China.
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Nov 09, 2018 08:08 JST
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA, an orally available kinase inhibitor discovered by Eisai, in combination with Merck's & Co., Inc.'s anti-PD-1 therapy KEYTRUDA in three different tumor types - metastatic non-small cell lung cancer (NSCLC), metastatic melanoma and metastatic urothelial carcinoma.
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
Nov 08, 2018 14:38 JST
Eisai Co., Ltd. and Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. announced today that EA Pharma has entered into an industry-academia-government joint research agreement with six related joint research organizations, and that research activities have fully commenced.
Eisai Commences Full-Scale Operation of New Suzhou Plant in China
Nov 08, 2018 08:43 JST
Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly.
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD
Oct 29, 2018 08:45 JST
Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease (CTAD) meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension (LTE) of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD.
Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-Wake Rhythm Disorder in Patients With Alzheimer's Disease
Oct 26, 2018 08:32 JST
Eisai Co., Ltd. announced that Eisai presented new data from Study 202, a Phase II evaluation of lemborexant, an investigational sleep-wake regulation agent, for the treatment of Irregular Sleep-Wake Rhythm Disorder (ISWRD) in patients with mild to moderate Alzheimer's disease.
Eisai and Biogen Announce Presentation of Additional Data from Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease
Oct 26, 2018 07:03 JST
Eisai presented the latest data from the Phase II clinical study (Study 201) of BAN2401 at a symposium session titled "Clinical and Biomarker Updates from BAN2401 Study 201 in Early Alzheimer's Disease" held on October 25 at the 11th CTAD conference in Barcelona, Spain.
Eisai to Present Latest Data on Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination and Exploratory Research
Oct 25, 2018 08:05 JST
Eisai Co., Ltd. announced today that the latest data regarding its in-house discovered kinase inhibitor lenvatinib mesylate, in combination with Merck & Co.'s anti-PD-1 therapy pembrolizumab, and exploratory research on the STING (stimulator of interferon genes) agonist E7766 as cancer immunotherapy will be presented during the 33rd Annual Meeting of the SITC.
Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide
Oct 23, 2018 14:13 JST
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson's disease treatment ME2125 (safinamide mesylate, "safinamide").
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan
Oct 22, 2018 16:34 JST
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that the two companies have commenced joint medical and marketing activities for tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in Japan.
Eisai: Discovery of Candidate Compound as Potential Treatment for Parkinson's Disease Using iPS Cells
Oct 19, 2018 11:18 JST
A joint research group centered around Professor Hideyuki Okano and Associate Professor Jun Kohyama, Department of Physiology of the Keio University School of Medicine, together with a research group of Eisai Co., Ltd. has identified a compound that has the potential to be a treatment for Parkinson's disease by using dopaminergic neurons differentiated from induced pluripotent stem (iPS) cells from patients with familial Parkinson's disease.
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference
Oct 18, 2018 08:03 JST
Eisai Co., Ltd. announced today that five oral presentations including a symposium, and two poster presentations.
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Oct 17, 2018 08:51 JST
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Latin America With Eurofarma
Oct 16, 2018 17:38 JST
Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for development and sales in each country.
Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China
Oct 12, 2018 13:48 JST
This application for perampanel in partial onset seizures in China was based on the results of three Phase III clinical studies conducted mainly in Europe and the United States, as well as the results of a Phase III clinical study (Study 335) conducted mainly in Asia including China and Japan.
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2018 Congress
Oct 10, 2018 14:35 JST
At the ESMO 2018 Congress, there will be an oral presentation on tumor growth rate prior to treatment administration and efficacy of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
New Data on Effect of Anti-Obesity Agent BELVIQ on Prevention and Remission of Type 2 Diabetes Presented at The European Association for the Study of Diabetes and Published in The Lancet
Oct 05, 2018 09:30 JST
This new analysis assessed metabolic effects on enrolled patients with T2DM or pre-diabetes (higher than normal blood sugar levels prior to incidence of diabetes) at baseline, as well as patients with normoglycemia.
Eisai's Fycompa Newly Approved by U.S. FDA as Treatment for Partial-Onset Seizures in Pediatric Patients with Epilepsy
Oct 01, 2018 07:48 JST
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. FDA for an indication expansion for Eisai's antiepileptic drug (AED) Fycompa (perampanel) to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older. Fycompa was designated for Priority Review by the FDA, and was approved approximately six months after submission.
Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC
Sep 05, 2018 14:28 JST
Eisai Co., Ltd. and Merck & Co. known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration (NMPA) approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Eisai Receives Approval for Partial Label Change for Vascular Embolization Device DC Bead
Sep 03, 2018 14:50 JST
Eisai Co., Ltd. announced that it has received approval for a partial label change for the vascular embolization device DC Bead (specially controlled medical device) in Japan.
Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea
Aug 30, 2018 09:36 JST
Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) from the Ministry of Food and Drug Safety (MFDS) in South Korea.
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab
Aug 29, 2018 10:25 JST
Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension (LTE) Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia.
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ
Aug 28, 2018 09:11 JST
The average change in weight from baseline was -4.2 kg with BELVIQ and -1.4 kg with placebo, translating to a 2.8 kg greater net weight loss with BELVIQ (nominal p-value<0.001).
NEC Takes Top Spot as Worldwide Market Leader in MZA's Global Call Control (PBX-IP PBX) Market Report
Dec 14, 2018 15:40 JST
"docomo Money Transfer" Mobile Remittance Service to Add China and Thailand
Dec 14, 2018 14:34 JST
Hitachi to Transfer Shares in Hitachi Procurement Service to Infosys, Panasonic, and PASONA
Dec 14, 2018 14:10 JST
Mitsubishi Corporation to Participate in Carbon Fiber Reprocessing Business in the UK
Dec 14, 2018 12:53 JST
Mitsubishi Shipbuilding Holds Christening Ceremony for LPG Carrier "LAUREL PRIME"
Dec 14, 2018 11:13 JST
NSITEXE Develops Test Chip with Next-generation Semiconductor IP Core Called a DFP
Dec 13, 2018 18:33 JST
NEC: Members Selected for the Research Program for the Development of a Quantum Annealing Machine Enabling High-Efficiency, High-Speed Processing
Dec 13, 2018 17:37 JST
Mitsubishi Motors to Relocate to a New Headquarters
Dec 13, 2018 17:20 JST
Production Milestone for Pratt & Whitney GTF PW1200G Engine at Mitsubishi Heavy Industries Aero Engines in Japan
Dec 13, 2018 10:28 JST
Mitsubishi Motors Secures Largest Fleet Sale of XPANDER to Garuda Indonesia
Dec 12, 2018 14:04 JST
Mitsubishi Corporation: Smart Meter Data Collection System 'Experiment' Launched in Hamamatsu
Dec 12, 2018 13:20 JST
GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics
Dec 12, 2018 10:06 JST
Showa Denko Announces Notice Regarding the Repurchase of Own Shares
Dec 11, 2018 14:00 JST
Showa Denko Forecasts Payment of Term-end Dividend
Dec 11, 2018 14:00 JST
Showa Denko Maps Out New Medium-term Business Plan "The TOP 2021"
Dec 11, 2018 14:00 JST
MHPS: Midwest Utility Orders Game-Changing SmartER GAC Gas Turbine
Dec 10, 2018 15:42 JST
TOYOTA GAZOO Racing to Exhibit GR Supra Super GT Concept at the Tokyo Auto Salon
Dec 10, 2018 11:30 JST
MHPS Receives Trainees from Vietnam Electricity (EVN)
Dec 10, 2018 11:05 JST
Hitachi Automotive Systems to Transfer its Commercial Vehicle Steering Business to Knorr-Bremse
Dec 10, 2018 09:39 JST
MHI Completes Capital-related Measures Affecting Mitsubishi Aircraft Corporation
Dec 07, 2018 13:46 JST
More Latest Release >>